How many drugs treat Crohn's disease?

Drug Landscape tracks 10 marketed treatments for Crohn's disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/crohn-s-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Crohn's disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Crohn's disease (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Crohn's disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Skyrizi	RISANKIZUMAB	AbbVie	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha	2019-01-01
Cimzia	CERTOLIZUMAB PEGOL	UCB	Tumor Necrosis Factor Blocker [EPC]	TNFα	2008-01-01
Tysabri	NATALIZUMAB	Biogen Idec	Integrin Receptor Antagonist [EPC]	α4β1 and α4β7 integrins	2004-01-01
Humira	ADALIMUMAB	AbbVie	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Abrilada	Adalimumab-Afzb	AbbVie	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Remicade	Infliximab-Dyyb	Johnson & Johnson	TNF blocker	Tumor Necrosis Factor alpha (TNFα)	1998-01-01
Remicade	INFLIXIMAB	Johnson & Johnson	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	1998-01-01
Pulmicort Respules	BUDESONIDE	AstraZeneca K.K.	Corticosteroid [EPC]	Glucocorticoid receptor	1994-01-01
Verdeso	DESONIDE	Padagis Us	Corticosteroid [EPC]	Glucocorticoid receptor	1972-01-01
Imuran	AZATHIOPRINE	Legacy Pharma	Purine Antimetabolite [EPC]	ATP-binding cassette sub-family G member 2	1968-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 6 drugs in Crohn's disease
Johnson & Johnson · 4 drugs in Crohn's disease
· 4 drugs in Crohn's disease
AbbVie · 3 drugs in Crohn's disease
Generic (originally Schering) · 2 drugs in Crohn's disease
Biogen Idec · 1 drug in Crohn's disease
Generic (originally Upjohn/Pfizer) · 1 drug in Crohn's disease
Biocon Biologics UK Ltd · 1 drug in Crohn's disease
Generic (originally Merck/Upjohn) · 1 drug in Crohn's disease
Biocad · 1 drug in Crohn's disease
Generic (originally Merck) · 1 drug in Crohn's disease
Generic (originally Lederle Laboratories) · 1 drug in Crohn's disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Crohn's disease:

Cite this brief

Drug Landscape (2026). Crohn's disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/crohn-s-disease. Accessed 2026-06-10.

Crohn's disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing